RET and medullary thyroid gland carcinoma: In June 2023, Genentech (Roche Group) announced the voluntary withdrawal of the US indication for RET-mutant MTC, which had previously been granted accelerated approval (December 2020), citing that it was not feasible to pursue pralsetinib in this indication for full approval [25,26].